Baidu
map

Gut:常见遗传变异对结直肠癌风险具有累积影响

2013-05-10 高晓方 编译 中国医学论坛报

  英国一项研究表明,基因型资料可提供年龄、性别和家族史等结直肠癌危险因素之外的附加信息,用以预测结直肠癌的发病风险。论文于4月22日在线发表于《消化道》(Gut)杂志。   研究纳入9个欧洲人群数据库,制定和验证了结直肠癌风险预测模型。   研究者利用二元逻辑回归分析法,评估了年龄、性别、家族史和10个易感基因位点基因型的综合效应,并利用病例对照资料得出风险模型,然后,利用内部交叉验证和外部

  英国一项研究表明,基因型资料可提供年龄、性别和家族史等结直肠癌危险因素之外的附加信息,用以预测结直肠癌的发病风险。论文于4月22日在线发表于《消化道》(Gut)杂志。

  研究纳入9个欧洲人群数据库,制定和验证了结直肠癌风险预测模型。

  研究者利用二元逻辑回归分析法,评估了年龄、性别、家族史和10个易感基因位点基因型的综合效应,并利用病例对照资料得出风险模型,然后,利用内部交叉验证和外部独立样本评估模型的鉴别力,最后,通过基因型和家族史模型分别估算了特定年龄和性别人群的10年绝对风险。

  结果显示,病例的风险等位基因的中位数量多于对照,并且被外部验证人群所证实。平均每等位基因风险升高为9%。虽然不同风险谱下,模型判别表现不佳,但在特定人群,模型具有发现预期10年绝对风险>5%亚组人群的实用性。

  研究者认为,尽管目前使用模型发现结直肠癌高风险人群已成为可能,但个体化遗传风险预测尚不可行。

结直肠癌相关的拓展阅读:


Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42 103 individuals
Objective
Colorectal cancer (CRC) has a substantial heritable component. Common genetic variation has been shown to contribute to CRC risk. A study was conducted in a large multi-population study to assess the feasibility of CRC risk prediction using common genetic variant data combined with other risk factors. A risk prediction model was built and applied to the Scottish population using available data.
Design
Nine populations of European descent were studied to develop and validate CRC risk prediction models. Binary logistic regression was used to assess the combined effect of age, gender, family history (FH) and genotypes at 10 susceptibility loci that individually only modestly influence CRC risk. Risk models were generated from case-control data incorporating genotypes alone (n=39 266) and in combination with gender, age and FH (n=11 324). Model discriminatory performance was assessed using 10-fold internal cross-validation and externally using 4187 independent samples. The 10-year absolute risk was estimated by modelling genotype and FH with age- and gender-specific population risks.
Results
The median number of risk alleles was greater in cases than controls (10 vs 9, p<2.2×10−16), confirmed in external validation sets (Sweden p=1.2×10−6, Finland p=2×10−5). The mean per-allele increase in risk was 9% (OR 1.09; 95% CI 1.05 to 1.13). Discriminative performance was poor across the risk spectrum (area under curve for genotypes alone 0.57; area under curve for genotype/age/gender/FH 0.59). However, modelling genotype data, FH, age and gender with Scottish population data shows the practicalities of identifying a subgroup with >5% predicted 10-year absolute risk.
Conclusion
Genotype data provide additional information that complements age, gender and FH as risk factors, but individualised genetic risk prediction is not currently feasible. Nonetheless, the modelling exercise suggests public health potential since it is possible to stratify the population into CRC risk categories, thereby informing targeted prevention and surveillance.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1705321, encodeId=816b1e053211f, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Mar 02 18:47:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061377, encodeId=2ab220613e7d1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Sep 25 13:47:00 CST 2013, time=2013-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342272, encodeId=c52913422e29e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377158, encodeId=fff013e71583b, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452619, encodeId=bcdd14526194b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1705321, encodeId=816b1e053211f, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Mar 02 18:47:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061377, encodeId=2ab220613e7d1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Sep 25 13:47:00 CST 2013, time=2013-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342272, encodeId=c52913422e29e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377158, encodeId=fff013e71583b, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452619, encodeId=bcdd14526194b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]
    2013-09-25 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1705321, encodeId=816b1e053211f, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Mar 02 18:47:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061377, encodeId=2ab220613e7d1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Sep 25 13:47:00 CST 2013, time=2013-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342272, encodeId=c52913422e29e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377158, encodeId=fff013e71583b, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452619, encodeId=bcdd14526194b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1705321, encodeId=816b1e053211f, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Mar 02 18:47:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061377, encodeId=2ab220613e7d1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Sep 25 13:47:00 CST 2013, time=2013-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342272, encodeId=c52913422e29e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377158, encodeId=fff013e71583b, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452619, encodeId=bcdd14526194b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1705321, encodeId=816b1e053211f, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Sun Mar 02 18:47:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061377, encodeId=2ab220613e7d1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Wed Sep 25 13:47:00 CST 2013, time=2013-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342272, encodeId=c52913422e29e, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377158, encodeId=fff013e71583b, content=<a href='/topic/show?id=007d9506920' target=_blank style='color:#2F92EE;'>#遗传变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95069, encryptionId=007d9506920, topicName=遗传变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452619, encodeId=bcdd14526194b, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun May 12 01:47:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]

相关资讯

Ann Surg:减肥手术或增加结直肠癌风险

目前减肥手术的长期癌症风险尚不透彻。但近期初步的流行病学观察结果及人类组织生物标记物相关研究表明,减肥手术后存在结直肠癌增加的风险。为确定减肥手术是否与结直肠癌长期风险增加有关,瑞典卡罗琳学院的Jesper Lagergren博士等人进行了一项研究,该研究结果发表于2013年3月6日在线出版的《外科学年鉴》(Annals of Surgery)杂志上。在1980年至2009年期间,在瑞典进行了一项

CA:体力活动或改善结直肠癌患者生存期

  日前,一项分析显示结直肠癌女性患者于诊断前后从事娱乐式体力活动(physical activity) 可显著改善生存(Cancer Causes Control. 2012;23:1939-1948)。“目前,我们已经有充足的理由说服患者加强锻炼,但这篇文章告诉我们强调患者于诊断后保持体力活动的重要性,”通信作者Amanda Phipps博士说,他是华盛顿西雅图Fred Hutchinson癌

Ann Surg:结直肠癌肝转移可行肝移植

影响患者存活率的术前因素   无法通过手术切除的结直肠癌肝转移(CLM)患者预后较差,其存活时间很少超过5年。尽管对于患有原发性及部分继发性恶性肿瘤的患者,经过筛选后进行肝脏移植术可获得较佳的预后,但是目前普遍认为,结直肠癌肝转移仍为肝脏移植的绝对禁忌症。在1995年之前,曾针对结直肠癌肝转移患者进行过数例肝脏移植术,但其预后很差(5年存活率:18%),因此最终放弃了针对结直肠癌肝转移患者进行的

CA Cancer J Clin:高水平体力活动显著改善结直肠癌患者生存期

日前,一项分析显示结直肠癌女性患者于诊断前后从事娱乐式体力活动(physical activity) 可显著改善生存(Cancer Causes Control. 2012;23:1939-1948)。“目前,我们已经有充足的理由说服患者加强锻炼,但这篇文章告诉我们强调患者于诊断后保持体力活动的重要性,”通信作者Amanda Phipps博士说,他是华盛顿西雅图Fred Hutchinson癌症研

Nature reviews:2012年结直肠癌研究的里程碑式突破

在过去的一年里,长期随访试验作为考验结肠直肠癌治疗的试金石,证实或推翻了若干治疗方案,并成功鉴定一款化学预防药物。对于转移性癌症,化疗在不可切除性原发肿瘤中的应用受到关注,一项随机3期试验为我们带来了新的治疗选择。结肠直肠癌的分子特征为我们提供了新的药物靶点。 2012年发表的研究成果正在改变我们治疗结直肠癌的方式。长期随访临床试验明确了阿司匹林用于林奇氏综合征患者癌症一级预防的有效性;证实了新

JCO:舒尼替尼联合FOLFIRI方案不优于FOLFIRI单独治疗结直肠癌

     一项国际多中心临床研究为我们带来了舒尼替尼在转移性结直肠癌一线治疗的阴性结果,结果发表在2013年4月第10期临床肿瘤学杂志(JCO),JCO April 1, 2013。        这项双盲,III期临床研究旨在确定,对于既往未经治疗的转移性结直肠癌(MCRC)患者,接受舒尼替尼加上FOLFIRI(氟尿嘧啶+亚

Baidu
map
Baidu
map
Baidu
map